Neurocrine Biosciences, Inc. NBIX

Company Overview

Neurocrine Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of therapies for neurological, neuroendocrine, and psychiatric disorders. The company operates within the biotechnology and pharmaceutical industries, with a strategic emphasis on diseases involving dysregulated nervous and endocrine system signaling. Its business model integrates internal research and development with selective collaborations to advance both proprietary and partnered drug candidates.

The company’s primary revenue driver is INGREZZA, a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. Neurocrine’s unique positioning is built on deep expertise in neurobiology, strong clinical development capabilities, and a focused therapeutic scope rather than broad diversification. Founded in 1992, the company initially concentrated on neuroendocrine disorders and gradually evolved into a fully integrated commercial-stage biotechnology company following the successful launch of INGREZZA in 2017.